Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials
In the Phase III INPULSIS® trials, treatment of patients with idiopathic pulmonary fibrosis (IPF) with nintedanib significantly reduced the annual rate of decline in forced vital capacity (FVC) versus placebo, consistent with slowing disease progression. However, nintedanib was not associated with a...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
30 January 2020
|
| In: |
Respiratory research
Year: 2020, Volume: 21 |
| ISSN: | 1465-993X |
| DOI: | 10.1186/s12931-020-1298-1 |
| Online Access: | Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1186/s12931-020-1298-1
|
| Author Notes: | Michael Kreuter, Wim A. Wuyts, Marlies Wijsenbeek, Sabrina Bajwah, Toby M. Maher, Susanne Stowasser, Natalia Male, Wibke Stansen, Nils Schoof, Leticia Orsatti and Jeffrey Swigris |
| Summary: | In the Phase III INPULSIS® trials, treatment of patients with idiopathic pulmonary fibrosis (IPF) with nintedanib significantly reduced the annual rate of decline in forced vital capacity (FVC) versus placebo, consistent with slowing disease progression. However, nintedanib was not associated with a benefit in health-related quality of life (HRQoL) assessed using the St George’s respiratory questionnaire (SGRQ). We aimed to further examine the impact of IPF progression on HRQoL and symptoms, and to explore the effect of nintedanib on HRQoL in patients from the INPULSIS® trials stratified by clinical factors associated with disease progression. |
|---|---|
| Item Description: | Gesehen am 02.04.2020 |
| Physical Description: | Online Resource |
| ISSN: | 1465-993X |
| DOI: | 10.1186/s12931-020-1298-1 |